ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

 

• Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%
• Total Rare Disease quarterly net revenues of $69.0 million, which includes:
  • Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, and
  • ILUVIEN® and YUTIQ® net revenues of $16.1 million
• Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-year
• Delivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-year
• Diluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70
• Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 million to $205.0 million, and adjusted non-GAAP diluted earnings per share of $6.27 to $6.62
• Rare Disease net revenues expected to represent 47% to 48% of total Company net revenues in 2025, including:
• Purified Cortrophin Gel net revenues of $265.0 million to $274.0 million, representing year-over-year growth of 33.8% to 38.3%, and
• ILUVIEN and YUTIQ net revenues of $97.0 million to $103.0 million

https://www.globenewswire.com/news-release/2025/05/09/3078088/0/en/ANI-Pharmaceuticals-Reports-Record-First-Quarter-2025-Financial-Results-and-Raises-2025-Guidance.html